The NemetzGroup

Mind vs. Machine in Asset Strategy

Jim Whalen — Tue, 24 Mar 2026 19:59:21 +0000

A well-informed asset strategy is an essential component of developing a novel therapy to meet critical patient needs.

The post Mind vs. Machine in Asset Strategy appeared first on The NemetzGroup.

Medical Affairs Today

Susan Nemetz — Wed, 25 Feb 2026 02:25:08 +0000

The biggest risk for pre-commercial companies is being singularly focused on a lean development program without planning for the additional data needed to support favorable pricing, clinical practice, and long-term market success. Early investment in medical affairs expertise is essential. Even a single FTE or experienced medical affairs consultant pays significant dividends later.

The post Medical Affairs Today appeared first on The NemetzGroup.

The Right Forum, at the Right Time

Liz Tufo — Wed, 28 Jan 2026 02:30:58 +0000

Some people need to “think out loud.” Others are eager to get right to the point. Toss in challenging schedules and countless communication platforms at our fingertips — a reality amplified by today's hybrid and virtual work environments — and the decision doesn’t get any easier. And, of course, this is unlikely to get better as more “content” is created in seconds due to the proliferation of AI.

The post The Right Forum, at the Right Time appeared first on The NemetzGroup.

100 Dots Connected: Reflecting on Eight Years of Conversations

Liz Tufo — Wed, 17 Dec 2025 12:45:00 +0000

The first edition of "Connecting the Dots" was published on September 29, 2017. Since Sue Nemetz penned that inaugural piece, 12 authors from our team have contributed their insight, experience, and perspective on the biopharma industry.

The post 100 Dots Connected: Reflecting on Eight Years of Conversations appeared first on The NemetzGroup.

Assuming the Role of Patient

Susan Nemetz — Thu, 20 Nov 2025 12:56:41 +0000

As readers of The NemetzGroup newsletter know, we often use this space to consider progress in biopharma, new technologies, and ways emerging companies bring therapies to market.

The post Assuming the Role of Patient appeared first on The NemetzGroup.

The “Forcing Function” of JPM

Jim Whalen — Tue, 28 Oct 2025 20:58:54 +0000

Biopharma companies need to balance many critical priorities, especially those that are pre-commercial.

The post The “Forcing Function” of JPM appeared first on The NemetzGroup.

Connecting in a Volatile Job Market

Susan Nemetz — Tue, 23 Sep 2025 21:33:42 +0000

What is the correct metaphor for today’s biopharma job market? A roller-coaster? A crater? A dark cloud? A correction?

The post Connecting in a Volatile Job Market appeared first on The NemetzGroup.

A Practical Guide to Biopharma Year-End Planning

The NemetzGroup — Wed, 27 Aug 2025 11:43:14 +0000

As summer winds down and vacations (sadly) come to an end, it’s a natural time to shift focus toward the close of the calendar year. Business leaders should prepare their organizations for a landscape that will be shaped by rapid technological changes, evolving market demands, and increasing global challenges.

The post A Practical Guide to Biopharma Year-End Planning appeared first on The NemetzGroup.

Building Credibility as a New Leader

Liz Tufo — Wed, 23 Jul 2025 12:50:12 +0000

Credibility is essential for leaders in any industry, but in the high-stakes world of pharma and biotech, it is even more critical.

The post Building Credibility as a New Leader appeared first on The NemetzGroup.

BIO and Boston: The Global Stage and HLYB

Susan Nemetz — Tue, 24 Jun 2025 21:43:25 +0000

Attending a large conference, medical congress, or trade show can be both exhausting and exhilarating. The decision to go in the first place depends on one’s goals, the expected ROI, and perspectives on who else might be attending.

The post BIO and Boston: The Global Stage and HLYB appeared first on The NemetzGroup.